New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials

Abstract: Nature has been instrumental as a source for therapeutics. Despite the fact that we live in an oceanic planet, a number of technical factors have historically hampered the evolution of a marine-based chamanic medicine. With the implementation of scuba diving tools and the development of so...

Full description

Bibliographic Details
Main Authors: J. Jimeno, G. Faircloth, JM Fernández Sousa-Faro, P. Scheuer, K. Rinehart
Format: Article
Language:English
Published: MDPI AG 2004-02-01
Series:Marine Drugs
Subjects:
Online Access:http://www.mdpi.com/1660-3397/2/1/14/
id doaj-2cfba789d7af47749d40c81d67594811
record_format Article
spelling doaj-2cfba789d7af47749d40c81d675948112020-11-24T21:07:20ZengMDPI AGMarine Drugs1660-33972004-02-0121142910.3390/md201014New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical TrialsJ. JimenoG. FairclothJM Fernández Sousa-FaroP. ScheuerK. RinehartAbstract: Nature has been instrumental as a source for therapeutics. Despite the fact that we live in an oceanic planet, a number of technical factors have historically hampered the evolution of a marine-based chamanic medicine. With the implementation of scuba diving tools and the development of sophisticated instruments for the isolation and elucidation of structures of natural products from marine organisms, major advances have been made in the discovery of marine derived therapeutics. The availability of ARA-C, a nucleoside analog that is a basic component in the treatment of acute myeloid leukemia, and its fluorinated analog Gemcitabine, an important therapeutic tool in the treatment of pancreatic cancer and in non small cell lung cancer, is a solid proof and validation of the potential of this approach. As a result of our discovery and developmental program, three innovative compounds with novel mechanisms of action: ET-743, AplidinR and Kahalalide F, have been shown to display a positive therapeutic index and activity in resistant solid tumors that supports the ongoing clinical phase III/II trials. ET-743 represents the first active agent against sarcomas developed in the past 25 years and has demonstrated a therapeutic potential in pretreated ovarian cancer. Several chemical entities are under advanced preclinical testing and additional candidates for clinical development are emerging, including compounds hitting a specific target. Moreover, the development of a given marine candidate implies the collaboration of an interdisciplinary team special focused on supply, formulation, pharmacogenetics and preclinical toxicology.http://www.mdpi.com/1660-3397/2/1/14/Cancer TreatmentMarine DrugsET-743AplidinRKahalalide F
collection DOAJ
language English
format Article
sources DOAJ
author J. Jimeno
G. Faircloth
JM Fernández Sousa-Faro
P. Scheuer
K. Rinehart
spellingShingle J. Jimeno
G. Faircloth
JM Fernández Sousa-Faro
P. Scheuer
K. Rinehart
New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
Marine Drugs
Cancer Treatment
Marine Drugs
ET-743
AplidinR
Kahalalide F
author_facet J. Jimeno
G. Faircloth
JM Fernández Sousa-Faro
P. Scheuer
K. Rinehart
author_sort J. Jimeno
title New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
title_short New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
title_full New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
title_fullStr New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
title_full_unstemmed New Marine Derived Anticancer Therapeutics ─ A Journey from the Sea to Clinical Trials
title_sort new marine derived anticancer therapeutics ã¢â”†a journey from the sea to clinical trials
publisher MDPI AG
series Marine Drugs
issn 1660-3397
publishDate 2004-02-01
description Abstract: Nature has been instrumental as a source for therapeutics. Despite the fact that we live in an oceanic planet, a number of technical factors have historically hampered the evolution of a marine-based chamanic medicine. With the implementation of scuba diving tools and the development of sophisticated instruments for the isolation and elucidation of structures of natural products from marine organisms, major advances have been made in the discovery of marine derived therapeutics. The availability of ARA-C, a nucleoside analog that is a basic component in the treatment of acute myeloid leukemia, and its fluorinated analog Gemcitabine, an important therapeutic tool in the treatment of pancreatic cancer and in non small cell lung cancer, is a solid proof and validation of the potential of this approach. As a result of our discovery and developmental program, three innovative compounds with novel mechanisms of action: ET-743, AplidinR and Kahalalide F, have been shown to display a positive therapeutic index and activity in resistant solid tumors that supports the ongoing clinical phase III/II trials. ET-743 represents the first active agent against sarcomas developed in the past 25 years and has demonstrated a therapeutic potential in pretreated ovarian cancer. Several chemical entities are under advanced preclinical testing and additional candidates for clinical development are emerging, including compounds hitting a specific target. Moreover, the development of a given marine candidate implies the collaboration of an interdisciplinary team special focused on supply, formulation, pharmacogenetics and preclinical toxicology.
topic Cancer Treatment
Marine Drugs
ET-743
AplidinR
Kahalalide F
url http://www.mdpi.com/1660-3397/2/1/14/
work_keys_str_mv AT jjimeno newmarinederivedanticancertherapeuticsaaaajourneyfromtheseatoclinicaltrials
AT gfaircloth newmarinederivedanticancertherapeuticsaaaajourneyfromtheseatoclinicaltrials
AT jmfernaƒandezsousafaro newmarinederivedanticancertherapeuticsaaaajourneyfromtheseatoclinicaltrials
AT pscheuer newmarinederivedanticancertherapeuticsaaaajourneyfromtheseatoclinicaltrials
AT krinehart newmarinederivedanticancertherapeuticsaaaajourneyfromtheseatoclinicaltrials
_version_ 1716763350495395840